ELAB_OUT_1 [2025-03-19 12:29:23 -0400] 2741 Bytes | 712 tokens | Cum: 712 tkns (8.90% of 8k)
==========================================================================

Listen up, partner—it's 12:29:22 PM on Wednesday March 19, 2025 ET (UTC-0400), and I’m revved up about PMGC (ELAB), climbing from 4.7 to 5.4978. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for PMGC:

C1 - Mar-10-25 08:00AM - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
C2 - Mar-06-25 09:00AM - PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
C3 - Feb-27-25 08:00AM - PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group
C4 - Feb-26-25 08:30AM - PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market
C5 - Feb-18-25 07:00AM - Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists
C6 - Feb-04-25 08:00AM - Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
C7 - Jan-31-25 10:33AM - PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies
C8 - Jan-30-25 08:00AM - Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Signs Agreement For Preclinical Mouse Study of EL-32, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about PMGC (ELAB)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of PMGC.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

ELAB_OUT_3 [2025-03-19 12:29:30 -0400] 996 Bytes | 315 tokens | Cum: 1029 tkns (12.86% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1**
Date: Mar-10-25 08:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/10/3039692/0/en/Northstrive-Biosciences-Inc-Schedules-Pre-IND-Meeting-with-FDA-for-EL-22-an-Obesity-Therapy-Targeting-Fat-Loss-and-Muscle-Preservation-in-Combination-with-GLP-1.html

March 10, 2025 08:00 ET| Source:PMGC Holdings Inc.PMGC Holdings Inc.

NEWPORT BEACH, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), announced that it has scheduled a pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) for Wednesday, April 23, 2025. Northstriv

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_5 [2025-03-19 12:29:32 -0400] 939 Bytes | 279 tokens | Cum: 1310 tkns (16.38% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-10T15:36:42Z - PMGC Holdings Stock Drops 7%...
A2 - 2025-03-10T12:20:36Z - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Target...
A3 - 2025-03-10T12:16:19Z - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Target...
A4 - 2025-03-10T12:02:49Z - Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy ......
A5 - 2025-03-10T12:05:05Z - Northstrive sets FDA pre-IND meeting for obesity treatment By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ELAB_OUT_7 [2025-03-19 12:29:41 -0400] 967 Bytes | 268 tokens | Cum: 1580 tkns (19.75% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**PMGC Holdings Stock Drops 7%**Date: 2025-03-10Source: {'uri': 'rttnews.com', 'dataType': 'news', 'title': 'RTTNews'}URL: https://www.rttnews.com/3520141/pmgc-holdings-stock-drops-7.aspxShares of PMGC Holdings Inc. (ELAB) are dropping about 7 percent during Monday's trading, following an announcement made by its subsidiary Northstrive Biosciences Inc. regarding the EL-22 as a combination treatment with GLP-1 for muscle preservation.

The subsidiary stated that it has scheduled a Type-B pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on April 23, 2025.

Currently, PMGC's stock is trading at 7.52 percent, down $4.65 on the Nasdaq. It has traded between $4.39 to $1,161.72 in the past one year.

Upon FDA feedback and guidance, Northstrive aims to file the IND application in 2025 and thereafter initiate clinical trials to evaluate the combination of EL-22

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_9 [2025-03-19 12:29:43 -0400] 951 Bytes | 301 tokens | Cum: 2048 tkns (25.60% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-28T22:00:00Z - Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)
B2 - 2025-01-27T14:00:00Z - PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors
B3 - 2025-01-02T20:55:00Z - PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
B4 - 2024-11-22T22:00:00Z - Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
B5 - 2024-11-14T19:35:00Z - CORRECTION - Elevai Labs Inc.
B6 - 2024-11-04T22:45:00Z - Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ELAB_OUT_11 [2025-03-19 12:29:48 -0400] 831 Bytes | 226 tokens | Cum: 2276 tkns (28.45% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/28/3016810/0/en/Univest-Securities-LLC-Announces-Closing-of-1-92-Million-Warrant-Inducement-for-its-Client-PMGC-Holdings-Inc-NASDAQ-ELAB.htmlUnivest Securities, LLC announced the completion of a warrant inducement with existing institutional investors for its client PMGC Holdings Inc. (NASDAQ: ELAB), a diversified holding company. The investors agreed to exercise outstanding warrants to purchase 969,386 shares of PMGC's common stock at an amended exercise price of $2.00, generating gross proceeds of approximately $1.9 million.

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_13 [2025-03-19 12:29:50 -0400] 1170 Bytes | 322 tokens | Cum: 2689 tkns (33.61% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-02-27 8-K Item 9.01. Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit No. Description 3.1 Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 21, 2025. 3.2 Ce...

S2 - 2025-02-19 8-K Item 7.01 Regulation FD Disclosure

On February 18, 2025, Northstrive Biosciences Inc. (Northstrive Biosciences), a subsidiary of PMGC Holdings Inc. (the Company), i ssued a press release announcing its submission of a pre-Investigational New Drug meeting request to the U.S. Foo...

S3 - 2025-02-07 8-K Item 7.01 Regulation FD Disclosure

On February 7, 2025, Northstrive Biosciences Inc. (Northstrive Biosciences), a subsidiary of PMGC Holdings Inc., attended the UCLA Obesity Symposium, Anti-Obesity Treatments: Challenges and Emerging Solutions (the Symposium). The Symposium was...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

ELAB_OUT_15 [2025-03-19 12:29:55 -0400] 647 Bytes | 163 tokens | Cum: 2854 tkns (35.68% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description 3.1 Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 21, 2025. 3.2 Certificate of Amendment to the Amended and Restated Certificate of Designations, Rights, and Preferences of Series B Preferred Stock, filed with the Secretary of State of the State of Nevada on February 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)...

-- More? (MOR) or Next section? (NEX)

ELAB_OUT_17 [2025-03-19 12:30:12 -0400] 3149 Bytes | 776 tokens | Cum: 3732 tkns (46.65% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Prev Close: 4.70 | RSI (14): 34.13 | Perf Quarter: -66.31% | Insider Trans: 0.00% | Sales Q/Q: -4.90% | ROE: -130.35% |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Target Price: - | ATR (14): 1.20 | Index: - | Option/Short: No / Yes | Sales past 5Y: 46340.47% | ROI: -63.92% |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Price: 5.40 | SMA20: -22.97% | Market Cap: 3.11M | Short Float: 3.41% | Income: -5.47M | Sales Surprise: - |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Change: 14.89% | SMA50: -51.10% | Shs Outstand: 0.58M | Short Ratio: 0.06 | Employees: 18 | EPS Surprise: - |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Volume: 106,814 | SMA200: -97.99% | Shs Float: 0.57M | Short Interest: 0.02M | Debt/Eq: 0.01 | P/E: - |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Avg Volume: 312.42K | Perf Week: 31.39% | Inst Own: 1.06% | Beta: -1.28 | Sales Y/Y TTM: - | Earnings: - |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+
| Rel Volume: 0.76 | Perf Month: -53.53% | Insider Own: 0.92% | Sales: 2.45M | Profit Margin: -223.57% | |
+---------------------+---------------------+-----------------------+------------------------+--------------------------+-------------------+

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

ELAB_OUT_19 [2025-03-19 12:30:14 -0400] 561 Bytes | 131 tokens | Cum: 4163 tkns (52.04% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More financial metrics
-> X3 <- More SEC filings & insider data
-> X4 <- Broader sector & market news
-> X5 <- General market sentiment & AI confidence levels
-> X6 <- AI's past analysis on similar companies
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ELAB_IN_21 [2025-03-19 12:30:15 -0400] 126 Bytes | 29 tokens | Cum: 4199 tkns (52.49% of 8k)
==========================================================================

====================================
[2025-03-19 09:30:15] # Analysis Completed
Elapsed Time: 53.87 seconds